Wells Fargo & Company assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX - Free Report) in a research note issued to investors on Thursday morning, Marketbeat reports. The brokerage issued an underweight rating and a $8.00 target price on the stock.
Other analysts have also issued reports about the company. Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a report on Thursday, March 13th. Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, HC Wainwright cut their price target on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research note on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $32.43.
View Our Latest Analysis on Bicara Therapeutics
Bicara Therapeutics Stock Performance
BCAX stock traded up $0.49 during trading on Thursday, hitting $13.14. The company had a trading volume of 130,914 shares, compared to its average volume of 469,766. Bicara Therapeutics has a one year low of $8.91 and a one year high of $28.09. The business has a 50-day moving average of $12.66 and a 200-day moving average of $16.22.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). As a group, research analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current year.
Institutional Trading of Bicara Therapeutics
A number of large investors have recently modified their holdings of BCAX. Geode Capital Management LLC bought a new stake in Bicara Therapeutics during the third quarter valued at approximately $1,239,000. Barclays PLC purchased a new position in Bicara Therapeutics in the third quarter worth $255,000. Bank of New York Mellon Corp purchased a new stake in Bicara Therapeutics during the fourth quarter valued at about $701,000. Jane Street Group LLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $309,000. Finally, Rhumbline Advisers bought a new stake in Bicara Therapeutics in the 4th quarter worth approximately $331,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
